Marlissa Kit
Product Images NDC 68462-388

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Marlissa (NDC 68462-388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn

Marlissa is an oral contraceptive containing 615mg of levonorgestrel and 0.03mg of ethinyl estradiol per each of the 21 light orange or orange tablets. It comes in a package of three blisters, each containing 28 tablets. The usual dosage is one tablet per day for 21 days, followed by a 7-day break. Each blister pack has a unique NDC number. The storage temperature must be controlled, and customers can contact a phone number for more information.*

FDA Label Image

Figure 2

This appears to be a list of studies conducted to compare the use of combined oral contraceptives (COC) versus never using them, and current users versus never-users. The studies include the NICHD Women's Care Study, French E3N Cohort Study, Shanghai Women's Health Study, Nurses' Health Study II, Danish Sex Hormone Register Study, and Oxford Family Planning Study. The results are presented as effect estimates (OR, RR, HR) and confidence intervals for the various studies. There is also a chart with numbers ranging from -1.5 to 2.0, but without additional context or labels, it's unclear what it represents.*

FDA Label Image

Figure1

This is a statistics table regarding blood clotting in women based on their pregnancy status and contraceptive use. The table shows the number of women out of 10,000 who experienced blood clots in different categories, including non-pregnant women, women who do not use combined oral contraceptives, women who use combined oral contraceptives, women in early pregnancy, and women in postpartum (up to 12 weeks after childbirth). The pregnancy data is based on actual durations of pregnancy in reference studies.*

FDA Label Image

Figurea

FDA Label Image

Logo

This appears to be a company name, "Glenmark". It is likely a pharmaceutical company based on the context of the text.*

FDA Label Image

Structureee

FDA Label Image

Structurelevonorgestrel

FDA Label Image

Glenmark Logo (Image 05)

This appears to be a table or chart with various methods of birth control and their efficacy rates displayed in terms of pregnancies per 100 women. The methods include injections, intrauterine devices, sterilization, birth control pills, the skin patch, the vaginal ring, the diaphragm, spermicide, and withdrawal. There are also categories for pregnancies per 100 women over 55 years old and for fewer pregnancies overall. The text does not provide enough context or detail to give a complete description.*

FDA Label Image

Image 08

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.